Search the Newsreel

Is NeuroOne Medical Technologies Corp (NMTC) Positioned for Grow

Euroseas earnings beat by $0.61, revenue fell short of estimates

NeuroOne Medical Technologies (NASDAQ: NMTC) posts larger loss and flags going concern risk

NeuroOne Medical Technologies (NMTC) reported a deeper net loss of $2.01 million for Q3 2026 and $5.83 million for the nine months ended June 30, 2026, significantly larger than the previous year. The company's cash and cash equivalents dwindled to $2.05 million, leading management …

Form 8K Neuroone Medical Technologies Corp For: 13 August By Investing.com

This article announces that Neuroone Medical Technologies Corp filed a Form 8K on August 13. It includes the company's stock symbol (NMTC) and its current performance. The content primarily serves as a placeholder for the filing and does not provide further details about the …

NeuroOne posts Q3 FY2026 revenue up 16% to $2.0M; gross margin expands to 59.9%

NeuroOne (NMTC) reported a 16% increase in Q3 FY2026 product revenue to $1.97 million, with product gross margin expanding to 59.9%. Despite a net loss of $2.01 million, the company secured $2.7 million in new product orders and achieved ISO 13485:2016 certification. Significant progress …

Coeur Mining (CDE) Is Up 7.9% After Record Q2 Output and Share Buyback Announcement

Coeur Mining reported record second-quarter gold production, steady silver output, and sharply higher sales and net income, alongside full-year 2026 guidance for gold, silver, and copper. The company also announced a share buyback, indicating management's confidence and strategic capital allocation. This strong performance, especially …

NeuroOne Medical Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Euroseas Ltd. Reports Results for the Quarter Ended June 30, 2026 and Declares Quarterly Common Stock Dividend

Euroseas Ltd. announced strong financial results for the second quarter and first half of 2026, with significant net revenues and earnings per share, driven by high charter rates and low drydocking expenses. The company also declared a quarterly dividend of $0.80 per share and …

UBS verlaagt Coca-Cola Europacific Partners ondanks hogere Q2-omzet en volumes

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies Corporation reported strong fiscal Q3 2026 financial results, with product revenue increasing 16% year-over-year to $2.0 million and gross margins expanding to 59.9%. The company also announced $2.7 million in new product orders, received ISO 13485 Certification for international expansion, and …

Mizuho Financial Group (EURK) reports 0% ownership in Eureka Acquisition Corp

Keurig Dr Pepper, Inc $KDP Holdings Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its stake in Keurig Dr Pepper (NASDAQ:KDP) by 22.3% in the second quarter, bringing its total holdings to 714,051 shares valued at over $23 million. Other institutional investors also adjusted their positions in the company. Keurig Dr Pepper recently announced …

Stoneweg Europe Stapled Trust, Sponsor Explore Structural Changes to Boost Long-Term Value

UBS verlaagt rating Coca-Cola Europacific Partners wegens waardering

The 5 Most Interesting Analyst Questions From Keurig Dr Pepper’s Q2 Earnings Call

Keurig Dr Pepper reported robust Q2 revenue growth, driven by the JDE Peet’s integration and strong U.S. Refreshment Beverages performance, despite margin pressure from higher input costs in U.S. Coffee. The article highlights key analyst questions concerning growth drivers, CEO appointment timing for Global …

UBS downgrades Coca-Cola Europacific Partners stock rating on valuation By Investing.com

Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

CDE- A Standout Silver Play that Delivered a Record Quarter

I still think it's too early to say the silver and gold price corrections are over. That said, I don't think we are likely to see new lows. Meanwhile, Coeur Mining Inc. (CDE) is a precious metals producer that's firing on all cylinders, suggests …

Euro India Fresh Foods standalone net profit rises 124.24% in the June 2026 quarter

EURO เตรียมจัด Earnings Call อัปเดตงบ Q2-แผนธุรกิจครึ่งปีหลัง 17 ส.ค.นี้

Coeur Mining (CDE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 11:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mitchell J. KrebsExecutive Vice President and Chief Financial Officer - Thomas S. WhelanExecutive Vice President and Chief Operating Officer - Michael RoutledgeSenior …

Stoneweg Europe Stapled Trust evaluates management internalisation, posts 1.4% rise in H1 DPS to 0.06642 euro

Stoneweg Europe Stapled Trust's H1 Distributable Income Flat at EUR37 Million

Can Eureka Group Holdings (ASX:EGH) Unlock Further Growth From Its Latest Mandurah Asset?

NeuroPace (NPCE) Stock Price Faces Flat Revenue And Lingering Losses

What's Going On With Euro Sun Mining Inc Stock Wednesday?

Capital World Investors (NASDAQ: KDP) discloses 8.8% Keurig Dr Pepper stake

Capital World Investors, a division of Capital Research and Management Company, has disclosed an 8.8% beneficial ownership stake in Keurig Dr Pepper Inc., totaling 120,099,461 shares. This filing, a Schedule 13G/A, indicates that the firm holds sole voting power over 117,777,759 shares and sole …

Alto Neuroscience Q2 EPS beats estimates; completes $100M financing

Alto Neuroscience (NYSE: ANRO) reported a Q2 2026 EPS of $(0.65), exceeding analyst estimates of $(0.73). The company also completed a $100 million financing round in July 2026, boosting its pro forma cash position to approximately $338 million, which is expected to fund operations …

ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed a Schedule 13G/A, disclosing a collective beneficial ownership of 2,375,861 shares of ClearPoint Neuro, Inc. (CLPT) common stock. This represents 7.8% of the company's outstanding shares as of June 30, …

Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, widening from the previous year, primarily due to increased R&D expenses which surged to $22.1 million. Despite the loss, the company significantly strengthened its balance sheet, increasing cash and cash equivalents …

EuroDry (NASDAQ:EDRY) Director Sells 500 Shares

EuroDry Director Aristeidis Pittas sold 500 shares of the company's stock for $18,900, reducing his holdings by 0.65%. This sale occurred shortly after EuroDry announced strong quarterly EPS of $2.44, significantly beating estimates, though revenue slightly missed expectations. The stock is trading near its …

EuroSports Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role

Minerva Neurosciences (NERV) has promoted Anthony Aliquo to Chief Accounting Officer and principal accounting officer, effective August 10, 2026. This move includes an increase in his annual base salary to $296,696 and a performance bonus target of 35%. Frederick Ahlholm remains the Chief Financial …

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …